Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
02 2019
Historique:
received: 10 08 2018
accepted: 09 09 2018
pubmed: 24 9 2018
medline: 25 12 2019
entrez: 24 9 2018
Statut: ppublish

Résumé

Children with acute leukemia who relapse after hematopoietic cell transplantation (HCT) have few therapeutic options. We studied 251 children and young adults with acute myelogenous or lymphoblastic leukemia who underwent a second HCT for relapse after their first HCT. The median age at second HCT was 11 years, and the median interval between first and second HCT was 17 months. Most of the patients (n = 187; 75%) were in remission, received a myeloablative conditioning regimen (n = 157; 63%), and underwent unrelated donor HCT (n = 230; 92%). The 2-year probability of leukemia-free survival (LFS) was 33% after transplantation in patients in remission, compared with 19% after transplantation in patients not in remission (P = .02). The corresponding 8-year probabilities were 24% and 10% (P = .003). A higher rate of relapse contributed to the difference in LFS. The 2-year probability of relapse after transplantation was 42% in patients in remission and 56% in those in relapse (P = .05). The corresponding 8-year probabilities were 49% and 64% (P = .04). These data extend the findings of others showing that patients with a low disease burden are more likely to benefit from a second transplantation. Late relapse led to a 10% decrement in LFS beyond the second year after second HCT. This differs from first HCT, in which most relapses occur within 2 years after HCT.

Identifiants

pubmed: 30244103
pii: S1083-8791(18)30573-1
doi: 10.1016/j.bbmt.2018.09.016
pmc: PMC6339844
mid: NIHMS1510400
pii:
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-306

Subventions

Organisme : AHRQ HHS
ID : K12 HS023011
Pays : United States
Organisme : NHLBI NIH HHS
ID : U10 HL069294
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Références

N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Biol Blood Marrow Transplant. 2015 Jul;21(7):1266-72
pubmed: 25765555
Stat Med. 1997 Apr 30;16(8):901-10
pubmed: 9160487
Br J Haematol. 2000 Feb;108(2):400-7
pubmed: 10691873
Stat Med. 1999 Jun 30;18(12):1489-500
pubmed: 10398287
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9
pubmed: 25460355
J Clin Oncol. 2015 Apr 10;33(11):1275-84
pubmed: 25605857
Blood. 2014 Jan 2;123(1):133-40
pubmed: 24141369
J Clin Oncol. 2009 Jan 20;27(3):377-84
pubmed: 19064980
Biol Blood Marrow Transplant. 2018 Aug;24(8):1629-1642
pubmed: 29548831
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Bone Marrow Transplant. 2015 Dec;50(12):1508-12
pubmed: 26389832
Bone Marrow Transplant. 2009 Dec;44(12):769-77
pubmed: 19855439
Br J Haematol. 2000 Oct;111(1):292-302
pubmed: 11091216
Leukemia. 2002 Sep;16(9):1668-72
pubmed: 12200679
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Bone Marrow Transplant. 2015 Dec;50(12):1542-50
pubmed: 26367221
Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8
pubmed: 26631751
Blood. 2014 Nov 27;124(23):3345-55
pubmed: 25049280
J Clin Oncol. 2016 Dec 20;34(36):4381-4389
pubmed: 27998223
J Clin Oncol. 2001 Aug 15;19(16):3675-84
pubmed: 11504749
Cancer. 2013 Nov 15;119(22):4036-43
pubmed: 24006085
Biol Blood Marrow Transplant. 2017 Jan;23(1):87-95
pubmed: 27742575
Leukemia. 2012 Jun;26(6):1211-7
pubmed: 22290066
Biol Blood Marrow Transplant. 2017 Sep;23(9):1523-1530
pubmed: 28527984
J Clin Oncol. 2013 Sep 10;31(26):3259-71
pubmed: 23918951
Bone Marrow Transplant. 2004 Oct;34(8):721-7
pubmed: 15322568

Auteurs

Troy C Lund (TC)

Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota.

Kwang Woo Ahn (KW)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.

Heather R Tecca (HR)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Megan V Hilgers (MV)

Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota.

Hisham Abdel-Azim (H)

Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California.

Allistair Abraham (A)

Division of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC.

Miguel Angel Diaz (MA)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Sherif M Badawy (SM)

Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

Larisa Broglie (L)

Division of Pediatric Bone Marrow Transplantation, Columbia University Medical Center, New York, New York.

Valerie Brown (V)

Division of Pediatric Oncology/Hematology, Department of Pediatrics, Penn State Hershey Children's Hospital and College of Medicine, Hershey, Pennsylvania.

Christopher C Dvorak (CC)

Pediatric Allergy Immunology and Blood and Marrow Transplant Division, UCSF Benioff Children's Hospital, San Francisco, California.

Marta Gonzalez-Vicent (M)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Hasan Hashem (H)

Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.

Robert J Hayashi (RJ)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

David A Jacobsohn (DA)

Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC.

Michael W Kent (MW)

Atrium Health/Levine Children's Hospital, Charlotte, North Carolina.

Chi-Kong Li (CK)

Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

Steven P Margossian (SP)

Department of Pediatric Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.

Paul L Martin (PL)

Department of Pediatrics, Duke University, Durham, North Carolina.

Parinda Mehta (P)

Division of Bone Marrow Transplant and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Kasiani Myers (K)

Division of Bone Marrow Transplant and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Richard Olsson (R)

Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

Kristin Page (K)

Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina.

Michael A Pulsipher (MA)

Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California.

Peter J Shaw (PJ)

The Children's Hospital at Westmead, Westmead, New South Wales, Australia.

Angela R Smith (AR)

Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota.

Brandon M Triplett (BM)

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.

Michael R Verneris (MR)

Pediatric Hematology/Oncology/Bone Marrow Transplant, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Mary Eapen (M)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: meapen@mcw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH